Summary
43 / 100 · Bulios Score
What speaks for it
- It earns 21 USD a year on every 100 USD of invested capital.
- The share price is below the Bulios Fair Price.
What to watch
- The company made a loss over the last 12 months.
- Operating profit does not even cover the interest on its debt.
- Revenue fell by 8.7% a year over the last 3 years.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 12% a year over 5 years. Over the last 3 years it fell by 8.7% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $22.4M.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 4.8 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
High, safe- Yield
- 13.07%
The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Infrastructure Segment 98%
- Spectrum Segment 1.3%
- Life Sciences Segment (Pansend) 0.7%
By region
- UNITED STATES 98%
- All Other Geographic Locations 2.0%
Infrastructure Segment brings in 98% of revenue. Life Sciences Segment (Pansend) grew fastest, by 43% a year.
Segments in detail